急性髓系白血病定向治疗的血流可及骨髓蛋白质图谱
研究对健康及急性髓系白血病(AML)大鼠的血管进行生物素灌注,鉴定出超过1400种骨髓蛋白质,其中181种在AML中较正常骨髓过表达超过100倍,并验证了11种差异最显著的蛋白质,为开发靶向AML骨髓的单克隆抗体药物偶联物提供基础。
要点
- 鉴定出181种在AML中较正常骨髓过表达超过100倍的蛋白质。
- 验证了11种差异最显著的蛋白质,包括AML细胞和白血病修饰的细胞外基质(ECM)中的新抗原。
- 该图谱为开发靶向AML骨髓的抗体药物载体提供基础。
核心结论
- 所呈现的可靶向AML相关骨髓蛋白质图谱为开发单克隆抗体提供了有价值的基础,这些抗体可作为载体将细胞毒性药物、细胞因子或放射性核素定点递送至AML骨髓。
研究设计与样本
- 研究对健康和急性髓系白血病(AML)荷瘤大鼠的血管系统灌注生物素反应性酯衍生物,随后对生物素化蛋白质进行定量,以鉴定可从血流接近的AML相关骨髓抗原。
主要发现
- 共鉴定出超过1400种蛋白质。
- 181种蛋白质在AML中较正常骨髓过表达超过100倍。
- 通过免疫组织化学和共聚焦显微镜分析进一步验证了11种差异最显著的蛋白质,包括在AML细胞中高表达的新抗原(例如衔接蛋白相关蛋白复合物3 β2)和在白血病修饰的细胞外基质(ECM)中高表达的新抗原(例如胶原VI-α-1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tumor tissue but is also easily accessible for antibody therapeutics coming from the bloodstream. Here, we perfused the vasculature of healthy and acute myeloid leukemia (AML)-bearing rats with a reactive ester derivative of biotin and subsequently quantified the biotinylated proteins to identify AML-associated bone marrow (BM) antigens accessible from the bloodstream. In total, >1400 proteins were identified. Overall, 181 proteins were >100-fold overexpressed in AML as compared with normal BM. Eleven of the most differentially expressed proteins were further validated by immunohistochemistry and confocal microscopic analyses, including novel antigens highly expressed in AML cells (for example, adaptor-related protein complex 3 β2) and in the leukemia-modified extracellular matrix (ECM) (for example, collagen-VI-α-1). The presented atlas of targetable AML-associated BM proteins provides a valuable basis for the development of monoclonal antibodies that could be used as carriers for a site-specific pharmacodelivery of cytotoxic drugs, cytokines or radionuclides to the BM in AML.
引用
- Angenendt L, Reuter S, Kentrup D, et al. An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia. Leukemia. 2017. PMID: 28663580. doi:10.1038/leu.2017.208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。